STAAR Surgical (NAS: STAA) reported earnings on Mar. 6. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 30 (Q4), STAAR Surgical missed estimates on revenues and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share improved to zero.
Margins grew across the board.
STAAR Surgical booked revenue of $16.4 million. The five analysts polled by S&P Capital IQ expected to see net sales of $16.7 million on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $14.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.03. The five earnings estimates compiled by S&P Capital IQ predicted $0.02 per share on the same basis. GAAP EPS contracted to zero from the prior-year quarter's -$0.02.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 69.8%, 400 basis points better than the prior-year quarter. Operating margin was 4.1%, 780 basis points better than the prior-year quarter. Net margin was 0.7%, 550 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $17.1 million. On the bottom line, the average EPS estimate is $0.03.
Next year's average estimate for revenue is $73.0 million. The average EPS estimate is $0.15.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 87 members rating the stock outperform and 13 members rating it underperform. Among 27 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 20 give STAAR Surgical a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on STAAR Surgical is buy, with an average price target of $10.17.
The health-care investing landscape is littered with also-rans and a few major winners. Is STAAR Surgical performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
Add STAAR Surgical to My Watchlist.
At the time thisarticle was published
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.